期刊
JOURNAL OF INFECTIOUS DISEASES
卷 200, 期 7, 页码 1088-1095出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/605645
关键词
-
资金
- Intramural NIH HHS [Z99 AI999999, Z99 DE999999, Z01 AI000548-20] Funding Source: Medline
- NCRR NIH HHS [P51 RR000168] Funding Source: Medline
- NIAID NIH HHS [AI057552, R01 AI057552, R56 AI057552] Funding Source: Medline
Background. A herpes simplex virus (HSV)-2 candidate vaccine consisting of glycoprotein D (gD2) in alum and monophosphoryl lipid A (MPL) reduced genital herpes disease in HSV-1-seronegative women but not in men or HSV-1-seropositive women. Methods. To determine the effect of HSV-1 serostatus on effectiveness of different vaccines, we tested gD2 in alum/MPL, gD2 in Freund's adjuvant, and dl5-29 (a replication-defective HSV-2 mutant) in HSV-1-seropositive or HSV-1-seronegative guinea pigs. Results. In HSV-1-seronegative animals, dl5-29 induced the highest titers of neutralizing antibody, and after vaginal challenge with wild-type virus, dl5-29 resulted in lower rates of vaginal shedding, lower levels of HSV DNA in ganglia, and a trend for less acute and recurrent genital herpes, compared with the gD2 vaccines. In HSV-1-seropositive animals, all 3 vaccines induced similar titers of neutralizing antibodies and showed similar levels of protection against acute and recurrent genital herpes after vaginal challenge with wild-type virus, but dl5-29 reduced vaginal shedding after challenge more than did the gD2 vaccines. Conclusions. dl5-29 Is an effective vaccine in both HSV-1-seropositive and HSV-1- seronegative guinea pigs and was superior to gD2 vaccines in reducing virus shedding after challenge in both groups of animals. dl5-29 Might reduce transmission of HSV-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据